Regulatory T cells and immunodeficiency in mycosis fungoides and Sezary syndrome

被引:88
|
作者
Krejsgaard, T. [1 ,2 ]
Odum, N. [2 ]
Geisler, C.
Wasik, M. A. [3 ]
Woetmann, A. [2 ]
机构
[1] Univ Copenhagen, Dept Int Hlth Immunol & Microbiol, Panum Inst, DK-2200 Copenhagen N, Denmark
[2] Univ Copenhagen, Dept Biol, DK-2200 Copenhagen N, Denmark
[3] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA
关键词
cutaneous T-cell lymphoma; Sezary syndrome; immunodeficiency; regulatory T cells; FOXP3; mycosis fungoides; TUMOR-INFILTRATING LYMPHOCYTES; GROWTH-FACTOR-BETA; NF-KAPPA-B; FOXP3; EXPRESSION; FAS-LIGAND; CONSTITUTIVE ACTIVATION; MALIGNANT PROLIFERATION; CD127; LYMPHOMA-CELLS; RECEPTOR;
D O I
10.1038/leu.2011.237
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cutaneous T-cell lymphoma (CTCL) is the term for diseases characterized by primary accumulation of malignant T cells in the skin. Patients with the two predominant clinical forms of CTCL called mycosis fungoides (MF) and Sezary syndrome (SS) characteristically develop severe immunodeficiency during disease progression and consequently patients with advanced disease frequently die of infections and not from the tumor burden. For decades, it has been suspected that the malignant T cells actively drive the evolving immunodeficiency to avoid antitumor immunity, yet, the underlying mechanisms remain unclear. The identification of a subset of highly immunosuppressive regulatory T cells (Tregs) triggered a variety of studies investigating if MF and SS are malignant proliferations of Tregs but seemingly discordant findings have been reported. Here, we review the literature to clarify the role of Tregs in MF and SS and discuss the potential mechanisms driving the immunodeficiency. Leukemia (2012) 26, 424-432; doi:10.1038/leu.2011.237; published online 9 September 2011
引用
收藏
页码:424 / 432
页数:9
相关论文
共 50 条
  • [1] Regulatory T cells and immunodeficiency in mycosis fungoides and Sézary syndrome
    T Krejsgaard
    N Odum
    C Geisler
    M A Wasik
    A Woetmann
    Leukemia, 2012, 26 : 424 - 432
  • [2] Evidence for T-regulatory cell abberrations in Sezary syndrome and mycosis fungoides
    Apisarnthanarax, N.
    Massari, J. V.
    Goodman, W. A.
    McCormick, T. S.
    Cooper, K. D.
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2007, 127 : S44 - S44
  • [3] Mycosis fungoides and Sezary syndrome
    Costello, Regis
    Farnault, Laure
    Bonnet, Nathalie
    Le Treut, Therese
    Poullin, Pascale
    Kahn-Perles, Brigitte
    HEMATOLOGIE, 2011, 17 (06): : 411 - 421
  • [4] Mycosis fungoides and Sezary syndrome
    Diamandidou, E
    Cohen, PR
    Kurzrock, R
    BLOOD, 1996, 88 (07) : 2385 - 2409
  • [5] Mycosis fungoides and the Sezary syndrome
    Foss, F
    CURRENT OPINION IN ONCOLOGY, 2004, 16 (05) : 421 - 428
  • [6] Mycosis fungoides and Sezary syndrome
    Hwang, Sam T.
    Janik, John E.
    Jaffe, Elaine S.
    Wilson, Wyndham H.
    LANCET, 2008, 371 (9616): : 945 - 957
  • [7] Mycosis fungoides and the Sezary syndrome
    Kim, YH
    Hoppe, RT
    SEMINARS IN ONCOLOGY, 1999, 26 (03) : 276 - 289
  • [8] Mycosis fungoides and Sezary syndrome
    Lee, Hyewon
    BLOOD RESEARCH, 2023, 58 : 66 - 82
  • [9] MYCOSIS FUNGOIDES - SEZARY SYNDROME
    ROENIGK, HH
    TAYLOR, JG
    ARCHIVES OF DERMATOLOGY, 1970, 101 (02) : 244 - &
  • [10] Mycosis Fungoides and Sezary Syndrome
    Foss, Francine M.
    Girardi, Michael
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2017, 31 (02) : 297 - +